Designing Safer Medicines in Discovery: Current and Emerging Opportunities to Reduce Attrition

25 March 2011

Designing Safer Medicines in Discovery: Current and Emerging Opportunities to Reduce Attrition was held at SCI HQ, London on 17 March 2011, and organised by SCI's Fine Chemicals Group.

Available Conference Papers:

Programme/Flyer
The Safety Related Attrition Challenge: A Medicinal Chemist's Perspective Steve Swallow, AstraZeneca R&D
Medicinal Chemistry Strategies to Address Bioactivation Liabilities in Drug Discovery Thomas Baillie, University of Washington, USA
Approaches that can be applied in drug discovery to minimize the likelihood of drug-induced liver injury in man Gerry Kenna, AstraZeneca R&D
Reducing Attrition Risk: Evolution of an in silico 'Compound Safety Evaluator' Kevin Dack, Pfizer Worldwide R&D
ChEMBL & Structural Alerts Francis Atkinson, Chemogenomics Group
Medicinal Chemists: how can we reduce attrition? Juliet Simpson, GlaxoSmithKline
Newer methods of predicting toxicity: characterising mechanisms of toxicity (PART 1) ,
Newer methods of predicting toxicity: characterising mechanisms of toxicity (PART 2) Mark Gosink, Pfizer

News

Designing Safer Medicines in Discovery: Current and Emerging Opportunities to Reduce Attrition

Related Links